1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-C REPORT BY ISSUER OF SECURITIES QUOTED ON NASDAQ INTERDEALER QUOTATION SYSTEM Filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 and Rule 13a-17 or 15d-17 thereunder IDEC PHARMACEUTICALS CORPORATION - ------------------------------------------------------------------------------- (Exact name of issuer as specified in charter) 11011 TORREYANA ROAD, SAN DIEGO, CA 92121 - ------------------------------------------------------------------------------- (Address of principal executive offices) Issuer's telephone number, including area code (619) 550-8500 I. CHANGE IN NUMBER OF SHARES OUTSTANDING Indicate any change (increase or decrease) of five percent or more in the number of shares outstanding: 1. Title of security COMMON STOCK 2. Number of shares outstanding before the change 14,701,261 AS OF MARCH 31, 1996 3. Number of shares outstanding after the change 16,771,261 4. Effective date of change JUNE 12, 1996 5. Method of change: Specify method (such as merger, acquisition, exchange, distribution, stock split, reverse split, acquisition of stock for treasury, etc.) PUBLIC OFFERING Give brief description of transaction PUBLIC OFFERING FOR 2,070,000 SHARES OF COMMON STOCK - ------------------------------------------------------------------------------- - ------------------------------------------------------------------------------- - ------------------------------------------------------------------------------- II. CHANGE IN NAME OF ISSUER 1. Name prior to change N/A 2. Name after change N/A 3. Effective date of charter amendment changing name N/A 4. Date of shareholder approval of change, if required N/A Date June 21, 1996 /s/ PHILLIP M. SCHNEIDER ----------------------- ---------------------------------- Phillip M. Schneider Vice President and Chief Financial Officer